drugset / Trial / NCT05074420

A Study of Baricitinib (LY3009104) in Children With COVID-19

NCT05074420

Phase 3 Terminated 6 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.

Timeline

Start
2021-12-21
Primary completion
2024-09-05
Completion
2024-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule Oral

Indications